{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Ftrop2-tigit-for-nsclc-Ohj3sd13","width":444,"version":"1.0","type":"rich","title":"TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/2573a3ac-6b26-45f7-90ae-f44209d8045b/101759-esmo-trop2-tigit-lung-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/3dcc27ce-fe14-4e00-a958-43f3e9cd90a7\" height=\"200\" width=\"100%\" title=\"TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to experts Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer."}